Floatz logo

ALLOGENEIC HUMAN UMBILICAL CORD BLOOD

Myelodysplasia

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

315 Active assets in the Myelodysplasia cohort.

Asset / SponsorPhaseRating
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB

View all 50 →

Same molecule, other indications

ALLOGENEIC HUMAN UMBILICAL CORD BLOOD is also rated in:

acute lymphoblastic leukemiaDormant
B
Indicative ·
61 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
59 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →